Cheng Du Sheng Nuo Biotec Co. Ltd. A Asset Resilience Ratio
Cheng Du Sheng Nuo Biotec Co. Ltd. A asset resilience ratio. Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has an Asset Resilience Ratio of 3.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cheng Du Sheng Nuo Biotec Co. Ltd. A (2021–2024)
Asset resilience ratio of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2021 to 2024. This chart shows how Cheng Du Sheng Nuo Biotec Co. Ltd. A's Asset Resilience Ratio has changed over time. Read Cheng Du Sheng Nuo Biotec Co. Ltd. A total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cheng Du Sheng Nuo Biotec Co. Ltd. A asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥67.00 Million | 3.51% |
| Total Liquid Assets | CN¥67.00 Million | 3.51% |
Asset Resilience Insights
- Limited Liquidity: Cheng Du Sheng Nuo Biotec Co. Ltd. A maintains only 3.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Cheng Du Sheng Nuo Biotec Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Cheng Du Sheng Nuo Biotec Co. Ltd. A Asset Resilience Ratio by Year (2021–2024)
Cheng Du Sheng Nuo Biotec Co. Ltd. A asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Cheng Du Sheng Nuo Biotec Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.22% | CN¥20.16 Million ≈ $2.95 Million |
CN¥1.65 Billion ≈ $241.14 Million |
-2.58pp |
| 2023-12-31 | 3.80% | CN¥50.00 Million ≈ $7.32 Million |
CN¥1.32 Billion ≈ $192.53 Million |
-17.11pp |
| 2021-12-31 | 20.91% | CN¥200.00 Million ≈ $29.27 Million |
CN¥956.62 Million ≈ $139.98 Million |
-- |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more